Market News How it works Learn FAQ
| RCT 0.0827 8.67% | NU 12.59 -16.95% | EWZ 34.15 -19.82% | BBD 2.93 -28.01% | TGL 0.2427 9.57% | AZTR 1.53 113.99% | ITUB 7.7 -20.37% | XP 15.705 -48.36% | NVD 3.99 -4.77% | SRTM 0.3 -30.28% | WFF 0.0898 12.25% | SPCX 146.9 -0.40% | PBR 22.5 -13.99% | SHFS 0.094 -29.00% | SOXL 90.5 8.31% | INTC 90.47 4.04% | VALE 12 -3.23% | NVDA 216 2.39% | CLRO 4.97 52.92% | NOK 8.64 6.14% | JBLU 2.37 -9.71% | TSLL 10.76 10.25% | CRWV 55.19 1.76% | GCDT 0.1545 -12.27% | SOXS 47.98 -8.54% | RIG 6.53 1.87% | NWGL 0.0869 5.98% | ABEV 2.83 -14.24% | RWM 14.5 -0.34% | BITO 10.65 -1.66% | AAL 12.2 0.74% | GPUS 0.1785 5.68% | TSLG 5.38 10.47% | T 20.85 -0.38% | SGRY 23.25 47.62% | IREN 25.43 2.11% | INTR 4.68 -34.91% | SBS 4.73 -26.09% | NFLX 63.9 -2.96% | GRAB 2.71 -2.87% | TSLA 391.62 5.21% | QID 14.22 -2.27% | WULF 11.98 5.83% | TQQQ 68.43 3.23% | CIFR 7.71 -2.90% | RBNE 0.17 -10.53% | SID 0.9118 -22.73% | SPDN 8.5 -0.47% | VZ 43.1 -3.49% | LUCD 0.5007 21.82%
MGMagenta Therapeutics, Inc. logo

Magenta Therapeutics, Inc. (MGTA)

NASDAQ Global Market · Currency in USD
$0.70 ▼ -0.06 (-7.74%)
At close: Sep 11, 4:00 PM ET. Market closed.

Summary

Previous Close
$0.76
Open
$0.71
Day's Range
$0.69 – $0.76
52 Week Range
$0.32 – $1.81
Volume
375,912
Avg. Volume
195,193
Market Cap
$42.44M
Beta (5Y Monthly)
2.11
PE Ratio (TTM)
--
EPS (TTM)
-$49.21
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Magenta Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
67
CEO
Stephen F. Mahoney MBA

Magenta Therapeutics, Inc. is a biotechnology firm in the clinical development stage, dedicated to advancing therapies that leverage the transformative potential of stem cell transplantation for individuals afflicted with blood cancers, genetic illnesses, and autoimmune conditions. Among its key pipeline candidates is MGTA-117, an anti-CD117 antibody. This compound specifically targets hematopoietic stem cells (HSCs) and the genetically altered stem cells implicated in acute myeloid leukemia and myelodysplastic syndromes, and is currently progressing through Phase I/II clinical trials.

Earnings

DateEst.Actual
Nov 2, 2023-$0.30-$0.27Beat
Aug 3, 2023$0.19$0.05Miss
Jun 5, 2023$0.41-$8.21Miss
Mar 8, 2023-$0.27-$7.38Miss
Nov 3, 2022$0.31$0.27Miss
Aug 4, 2022$0.37$0.29Miss

Analyst view

Rating: Hold
Buy 40% · Hold 60% · Sell 0%

Get free alerts on MGTA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.